A Sagaliam további évet keres az Enzolytics leányvállalataival való megállapodásra | SPAC takarmány

SAgaliam Acquisition in a proxy filing proposes a 12-month extension Nov. 23, 2024 to complete a merger.

Sagaliam last month executed a binding business combination agreement for the purchase of Biogenysis, and Virogentics, operating subsidiaries of Enzolytics.

The SPAC in June amended a non-binding term sheet for the purchase of Enzolytics to $450 million. The initial term sheet called for a purchase price of $250 million.

Sagaliam expects to raise additional capital through a PIPE to fund the deal.

Enzolytics is a drug development company committed to commercializing its proprietary proteins and monoclonal antibodies to treat debilitating infectious diseases.

Sagaliam in March terminated a merger agreement with Arabian szórakozás.

The SPAC raised about $116 million in a December 2021 IPO, but lost almost 92% to redemptions in December 2022. The SPAC as of June held nearly $10 million in trust. Tovább.

Forrás: Sagaliam Seeks Additional Year to Seal Deal with Enzolytics Subsidiaries

• SEO által támogatott tartalom és PR terjesztés. Erősödjön még ma.
• PlatoData.Network Vertical Generative Ai. Erősítse meg magát. Hozzáférés itt.
• PlatoAiStream. Web3 Intelligence. Felerősített tudás. Hozzáférés itt.
• PlatoESG. Carbon, CleanTech, Energia, Környezet, Nap, Hulladékgazdálkodás. Hozzáférés itt.
• PlatoHealth. Biotechnológiai és klinikai vizsgálatok intelligencia. Hozzáférés itt.
• Forrás: https://spacfeed.com/sagaliam-seeks-additional-year-to-seal-deal-with-enzolytics-subsidiaries